| SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
| FORM 8-K |
| CURRENT REPORT |
| Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| Date of Report (Date of earliest event reported): | May 13, 2003
|
| Introgen Therapeutics, Inc.
(Exact name of registrant as specified in its charter) |
| Delaware
(State or other jurisdiction of incorporation) |
0-21291
(Commission File Number) |
74-2704230
(IRS Employer Identification No.) |
| 301 Congress Avenue, Suite 1850, Austin, Texas
78701
(Address of principal executive offices) (Zip Code) |
| Registrant’s telephone number, including area code: | (512) 708-9310
|
|
(Former name or former address, if changed since last report) |
| Item 7. Financial Statements and Exhibits. |
| (c) Exhibits. |
| 99.1 Press Release dated May 13, 2003. |
| Item 9. Regulation FD Disclosure. |
|
The press release filed as an exhibit to this report is being furnished under Item 12 (Furnishing of Earnings Releases) as contemplated by SEC Release Nos. 33-8176 and 33-8216. |
|
SIGNATURES |
| Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
| Dated: May 13, 2003 | INTROGEN THERAPEUTICS, INC |
|
James W. Albrecht, Jr. Chief Financial Officer |
| -2- |
| INDEX TO EXHIBITS |
| Exhibit Number |
Description of Document
|
| 99.1 | Press Release dated May 13, 2003. |